Review: Novel agents for advanced bladder cancer

Por Guru Sonpavde, Aymen A. Elfiky, Jonathan E. Rosenberg
Publicado em 2009-07-01

Gene expression in primary and metastatic kidney cancer to discover drivers of metastasis and targets for drug development

Por Zhao, Amy, Guru, Arjun, Guru, Sonpavde, Yang, Eddy, Li, Yufeng
Publicado no J Immunother Cancer (2015)

Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials

Por Ravi K. Paluri, Guru Sonpavde, Charity Morgan, Jacob Rojymon, Anastasia Hartzes Mar, Radhika Gangaraju
Publicado em 2019-11-01

TUBB4A interacts with MYH9 to protect the nucleus during cell migration and promotes prostate cancer via GSK3β/β-catenin signalling

Por Song Gao, Shuaibin Wang, Zhiying Zhao, Chao Zhang, Zhicao Liu, Ping Ye, Zhifang Xu, Baozhu Yi, Kai Jiao, Gurudatta A. Naik, Shi Wei, Soroush Rais-Bahrami, Sejong Bae, Wei-Hsiung Yang, Guru Sonpavde, Runhua Liu, Lizhong Wang
Publicado em 2022-05-01

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Por Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor, Prasanth Abraham, Jonathan E. Rosenberg
Publicado em 2017-08-01